Pub Date : 2020-11-01DOI: 10.1016/j.psym.2020.04.008
Lisa M. Horowitz Ph.D., M.P.H. , Deborah J. Snyder M.S.W. , Edwin D. Boudreaux Ph.D. , Jian-Ping He M.S. , Colin J. Harrington M.D. , June Cai M.D. , Cynthia A. Claassen Ph.D. , Joan E. Salhany M.B.A.H.C.M., R.N. , Tram Dao Psy.D. , John F. Chaves M.D. , David A. Jobes Ph.D. , Kathleen R. Merikangas Ph.D. , Jeffrey A. Bridge Ph.D. , Maryland Pao M.D.
Background
Few brief suicide risk screening instruments are validated for use in both adult and pediatric medical populations. Using the pediatric Ask Suicide-Screening Questions (ASQ) development study as a model, this study aimed to determine whether the ASQ is a valid suicide risk–screening instrument for use among adults medical patients, as well as to evaluate a set of other potential screening questions for use in adults.
Methods
Adult patients hospitalized on inpatient medical/surgical units from 4 hospitals were recruited to participate in a cross-sectional instrument-validation study. The 4-item ASQ and other candidate items were compared against the 25-item, previously validated Adult Suicidal Ideation Questionnaire as the criterion standard.
Results
A total of 727 adult medical inpatients completed the screening process. Compared with the Adult Suicidal Ideation Questionnaire, the ASQ performed best among the full set of candidate items, demonstrating strong psychometric properties, with a sensitivity of 100% (95% confidence interval = 90%–100%), a specificity of 89% (95% confidence interval = 86%–91%), and a negative predictive value of 100% (95% confidence interval = 99%–100%). A total of 4.8% (35/727) of the participants screened positive for suicide risk based on the standard criterion Adult Suicidal Ideation Questionnaire.
Conclusions
The ASQ is a valid and brief suicide risk–screening tool for use among adults. Screening medical/surgical inpatients for suicide risk can be performed effectively for both adult and pediatric patients using this brief, primary screener.
{"title":"Validation of the Ask Suicide-Screening Questions for Adult Medical Inpatients: A Brief Tool for All Ages","authors":"Lisa M. Horowitz Ph.D., M.P.H. , Deborah J. Snyder M.S.W. , Edwin D. Boudreaux Ph.D. , Jian-Ping He M.S. , Colin J. Harrington M.D. , June Cai M.D. , Cynthia A. Claassen Ph.D. , Joan E. Salhany M.B.A.H.C.M., R.N. , Tram Dao Psy.D. , John F. Chaves M.D. , David A. Jobes Ph.D. , Kathleen R. Merikangas Ph.D. , Jeffrey A. Bridge Ph.D. , Maryland Pao M.D.","doi":"10.1016/j.psym.2020.04.008","DOIUrl":"10.1016/j.psym.2020.04.008","url":null,"abstract":"<div><h3>Background</h3><p>Few brief suicide risk screening instruments are validated for use in both adult and pediatric medical populations. Using the pediatric Ask Suicide-Screening Questions (ASQ) development study as a model, this study aimed to determine whether the ASQ is a valid suicide risk–screening instrument for use among adults medical patients, as well as to evaluate a set of other potential screening questions for use in adults.</p></div><div><h3>Methods</h3><p>Adult patients hospitalized on inpatient medical/surgical units from 4 hospitals were recruited to participate in a cross-sectional instrument-validation study. The 4-item ASQ and other candidate items were compared against the 25-item, previously validated Adult Suicidal Ideation Questionnaire as the criterion standard.</p></div><div><h3>Results</h3><p>A total of 727 adult medical inpatients completed the screening process. Compared with the Adult Suicidal Ideation Questionnaire, the ASQ performed best among the full set of candidate items, demonstrating strong psychometric properties, with a sensitivity of 100% (95% confidence interval = 90%–100%), a specificity of 89% (95% confidence interval = 86%–91%), and a negative predictive value of 100% (95% confidence interval = 99%–100%). A total of 4.8% (35/727) of the participants screened positive for suicide risk based on the standard criterion Adult Suicidal Ideation Questionnaire.</p></div><div><h3>Conclusions</h3><p>The ASQ is a valid and brief suicide risk–screening tool for use among adults. Screening medical/surgical inpatients for suicide risk can be performed effectively for both adult and pediatric patients using this brief, primary screener.</p></div>","PeriodicalId":20746,"journal":{"name":"Psychosomatics","volume":"61 6","pages":"Pages 713-722"},"PeriodicalIF":3.4,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.psym.2020.04.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10786905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diagnostic Challenges and Treatment of the Neuropsychiatric Symptoms of Adult-Onset Niemann-Pick Type C With Electroconvulsive Therapy","authors":"Rachel Foels B.S. , Kimberly Hartney M.D. , Alexis Cohen-Oram M.D.","doi":"10.1016/j.psym.2020.06.011","DOIUrl":"10.1016/j.psym.2020.06.011","url":null,"abstract":"","PeriodicalId":20746,"journal":{"name":"Psychosomatics","volume":"61 6","pages":"Pages 752-755"},"PeriodicalIF":3.4,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.psym.2020.06.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38172987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-01DOI: 10.1016/j.psym.2020.06.006
Janice Chung B.S. , Prudhvi Bandi B.S. , Daniel B. Janiczak M.D. , Jason P. Caplan M.D. , Curtis A. McKnight M.D.
{"title":"The Use of Security Dogs in De-escalation of Agitated Patients","authors":"Janice Chung B.S. , Prudhvi Bandi B.S. , Daniel B. Janiczak M.D. , Jason P. Caplan M.D. , Curtis A. McKnight M.D.","doi":"10.1016/j.psym.2020.06.006","DOIUrl":"10.1016/j.psym.2020.06.006","url":null,"abstract":"","PeriodicalId":20746,"journal":{"name":"Psychosomatics","volume":"61 6","pages":"Pages 756-758"},"PeriodicalIF":3.4,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.psym.2020.06.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38155893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-01DOI: 10.1016/j.psym.2020.05.011
Christine Sawhill D.O. , David C. Fipps D.O. , Jennifer V. Palomo M.S. , Melanie Miller M.D.
{"title":"End-Stage Anorexia Nervosa: When to Say “When”—A Literature Review of an Ethically Complicated Case","authors":"Christine Sawhill D.O. , David C. Fipps D.O. , Jennifer V. Palomo M.S. , Melanie Miller M.D.","doi":"10.1016/j.psym.2020.05.011","DOIUrl":"10.1016/j.psym.2020.05.011","url":null,"abstract":"","PeriodicalId":20746,"journal":{"name":"Psychosomatics","volume":"61 6","pages":"Pages 779-786"},"PeriodicalIF":3.4,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.psym.2020.05.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38160848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-01DOI: 10.1016/j.psym.2020.05.013
Erica B. Baller M.D., M.S. , Charlotte S. Hogan M.D. , Mark A. Fusunyan M.D. , Ana Ivkovic M.D. , James W. Luccarelli M.D., D.Phil. , Elizabeth Madva M.D. , Mladen Nisavic M.D. , Nathan Praschan M.D., M.P.H. , Nadia V. Quijije M.D. , Scott R. Beach M.D. , Felicia A. Smith M.D.
Background
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the biggest health threats of our generation. A significant portion of patients are presenting with delirium and neuropsychiatric sequelae of the disease. Unique examination findings and responses to treatment have been identified.
Objective
In this article, we seek to provide pharmacologic and treatment recommendations specific to delirium in patients with COVID-19.
Methods
We performed a literature search reviewing the neuropsychiatric complications and treatments in prior coronavirus epidemics including Middle Eastern respiratory syndrome and severe acute respiratory syndrome coronaviruses, as well as the emerging literature regarding COVID-19. We also convened a work group of consultation-liaison psychiatrists actively managing patients with COVID-19 in our hospital. Finally, we synthesized these findings to provide preliminary pharmacologic recommendations for treating delirium in these patients.
Results
Delirium is frequently found in patients who test positive for COVID-19, even in the absence of respiratory symptoms. There appears to be a higher rate of agitation, myoclonus, abulia, and alogia. No data are currently available on the treatment of delirium in patients with COVID-19. Extrapolating from general delirium treatment, Middle Eastern respiratory syndrome/severe acute respiratory syndrome case reports, and our experience, preliminary recommendations for pharmacologic management have been assembled.
Conclusions
COVID-19 is associated with neuropsychiatric symptoms. Low-potency neuroleptics and alpha-2 adrenergic agents may be especially useful in this setting. Further research into the pathophysiology of COVID-19 will be key in developing more targeted treatment guidelines.
{"title":"Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19","authors":"Erica B. Baller M.D., M.S. , Charlotte S. Hogan M.D. , Mark A. Fusunyan M.D. , Ana Ivkovic M.D. , James W. Luccarelli M.D., D.Phil. , Elizabeth Madva M.D. , Mladen Nisavic M.D. , Nathan Praschan M.D., M.P.H. , Nadia V. Quijije M.D. , Scott R. Beach M.D. , Felicia A. Smith M.D.","doi":"10.1016/j.psym.2020.05.013","DOIUrl":"10.1016/j.psym.2020.05.013","url":null,"abstract":"<div><h3>Background</h3><p>The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the biggest health threats of our generation. A significant portion of patients are presenting with delirium and neuropsychiatric sequelae of the disease. Unique examination findings and responses to treatment have been identified.</p></div><div><h3>Objective</h3><p>In this article, we seek to provide pharmacologic and treatment recommendations specific to delirium in patients with COVID-19.</p></div><div><h3>Methods</h3><p>We performed a literature search reviewing the neuropsychiatric complications and treatments in prior coronavirus epidemics including Middle Eastern respiratory syndrome and severe acute respiratory syndrome coronaviruses, as well as the emerging literature regarding COVID-19. We also convened a work group of consultation-liaison psychiatrists actively managing patients with COVID-19 in our hospital. Finally, we synthesized these findings to provide preliminary pharmacologic recommendations for treating delirium in these patients.</p></div><div><h3>Results</h3><p>Delirium is frequently found in patients who test positive for COVID-19, even in the absence of respiratory symptoms. There appears to be a higher rate of agitation, myoclonus, abulia, and alogia. No data are currently available on the treatment of delirium in patients with COVID-19. Extrapolating from general delirium treatment, Middle Eastern respiratory syndrome/severe acute respiratory syndrome case reports, and our experience, preliminary recommendations for pharmacologic management have been assembled.</p></div><div><h3>Conclusions</h3><p>COVID-19 is associated with neuropsychiatric symptoms. Low-potency neuroleptics and alpha-2 adrenergic agents may be especially useful in this setting. Further research into the pathophysiology of COVID-19 will be key in developing more targeted treatment guidelines.</p></div>","PeriodicalId":20746,"journal":{"name":"Psychosomatics","volume":"61 6","pages":"Pages 585-596"},"PeriodicalIF":3.4,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.psym.2020.05.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38299579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-01DOI: 10.1016/j.psym.2020.07.005
Andrea Giacalone Ph.D., Gennaro Rocco Ph.D., Enzo Ruberti Ph.D.
{"title":"Physical Health and Psychosocial Considerations During the Coronavirus Disease 2019 Outbreak","authors":"Andrea Giacalone Ph.D., Gennaro Rocco Ph.D., Enzo Ruberti Ph.D.","doi":"10.1016/j.psym.2020.07.005","DOIUrl":"10.1016/j.psym.2020.07.005","url":null,"abstract":"","PeriodicalId":20746,"journal":{"name":"Psychosomatics","volume":"61 6","pages":"Pages 851-852"},"PeriodicalIF":3.4,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.psym.2020.07.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38322743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-01DOI: 10.1016/j.psym.2020.05.002
Mary A. LeCloux Ph.D. , Mathew Weimer M.D. , Stacey L. Culp Ph.D. , Karissa Bjorkgren B.S. , Samantha Service M.S. , John V. Campo M.D.
Objective
The purpose of this study was to evaluate the feasibility and impact of a suicide risk screening program in a rural West Virginia primary care practice.
Methods
Patients presenting for routine and sick visits were asked to participate in electronic suicide risk screening using the Ask Suicide-Screening Questions tool; screen positive individuals were assessed with the Ask Suicide-Screening Questions Brief Suicide Safety Assessment. Screening program feasibility was evaluated by the proportion of patients consenting to participate, participant Ask Suicide-Screening Questions and Brief Suicide Safety Assessment completion rates, and response to a question asking whether primary care providers should ask about suicide. Screening impact was evaluated quasi-experimentally by comparing electronic medical record documentation of suicide risk screening, assessment, and risk determination in practice patients before and after implementing the screening program.
Results
Over half of the patients approached agreed to participate in a research study about suicide (N = 196; 57.7%). Feasibility of the screening program was demonstrated by the high completion rates for the Ask Suicide-Screening Questions (99.0%) and the Brief Suicide Safety Assessment (100.0%) among study participants. Additionally, 95.4% (N = 187) of participants agreed primary care providers should screen patients for suicide. Suicide screening rates rose significantly between the baseline and intervention phases (5.8% to 61.0%; X2 = 200.61, P < 0.001), as did suicide risk detection rates (0.7% to 6.2%; X2 = 12.58, P < 0.001).
Conclusion
Suicide risk screening was feasible and well accepted by adult patients in rural primary care and has potential to improve suicide risk detection in this setting.
目的本研究的目的是评估自杀风险筛查项目在西弗吉尼亚州农村初级保健实践中的可行性和影响。方法采用“询问自杀筛查问题”(Ask suicide screening Questions)工具,要求就诊的患者参与电子自杀风险筛查;对筛查阳性个体进行自杀筛查问题简要自杀安全评估。筛选方案的可行性通过同意参与的患者比例、参与者询问自杀筛选问题和简要自杀安全评估完成率以及对初级保健提供者是否应该询问自杀问题的回答来评估。通过比较实施筛查计划前后患者自杀风险筛查、评估和风险确定的电子病历文件,对筛查的影响进行准实验评估。结果超过一半的患者同意参加一项关于自杀的研究(N = 196;57.7%)。筛选方案的可行性通过研究参与者自杀筛选问题的高完成率(99.0%)和简要自杀安全评估(100.0%)得到证明。此外,95.4% (N = 187)的参与者同意初级保健提供者应该对患者进行自杀筛查。自杀筛查率在基线和干预阶段之间显著上升(5.8%至61.0%;X2 = 200.61, P <0.001),自杀风险检出率也是如此(0.7%至6.2%;X2 = 12.58, P <0.001)。结论自杀风险筛查在农村初级保健成人患者中是可行的,且被广泛接受,具有提高自杀风险检测水平的潜力。
{"title":"The Feasibility and Impact of a Suicide Risk Screening Program in Rural Adult Primary Care: A Pilot Test of the Ask Suicide-Screening Questions Toolkit","authors":"Mary A. LeCloux Ph.D. , Mathew Weimer M.D. , Stacey L. Culp Ph.D. , Karissa Bjorkgren B.S. , Samantha Service M.S. , John V. Campo M.D.","doi":"10.1016/j.psym.2020.05.002","DOIUrl":"10.1016/j.psym.2020.05.002","url":null,"abstract":"<div><h3>Objective</h3><p>The purpose of this study was to evaluate the feasibility and impact of a suicide risk screening program in a rural West Virginia primary care practice.</p></div><div><h3>Methods</h3><p>Patients presenting for routine and sick visits were asked to participate in electronic suicide risk screening using the Ask Suicide-Screening Questions tool; screen positive individuals were assessed with the Ask Suicide-Screening Questions Brief Suicide Safety Assessment. Screening program feasibility was evaluated by the proportion of patients consenting to participate, participant Ask Suicide-Screening Questions and Brief Suicide Safety Assessment completion rates, and response to a question asking whether primary care providers should ask about suicide. Screening impact was evaluated quasi-experimentally by comparing electronic medical record documentation of suicide risk screening, assessment, and risk determination in practice patients before and after implementing the screening program.</p></div><div><h3>Results</h3><p>Over half of the patients approached agreed to participate in a research study about suicide (<em>N</em> = 196; 57.7%). Feasibility of the screening program was demonstrated by the high completion rates for the Ask Suicide-Screening Questions (99.0%) and the Brief Suicide Safety Assessment (100.0%) among study participants. Additionally, 95.4% (<em>N</em> = 187) of participants agreed primary care providers should screen patients for suicide. Suicide screening rates rose significantly between the baseline and intervention phases (5.8% to 61.0%; X<sup>2</sup> = 200.61, <em>P</em> < 0.001), as did suicide risk detection rates (0.7% to 6.2%; X<sup>2</sup> = 12.58, <em>P</em> < 0.001).</p></div><div><h3>Conclusion</h3><p>Suicide risk screening was feasible and well accepted by adult patients in rural primary care and has potential to improve suicide risk detection in this setting.</p></div>","PeriodicalId":20746,"journal":{"name":"Psychosomatics","volume":"61 6","pages":"Pages 698-706"},"PeriodicalIF":3.4,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.psym.2020.05.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38143657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}